Characteristics and the Side Effects of New MDR-TB Treatment in the Dr. Soetomo Hospital during 2016

Umi Fatmawati, Tutik Kusmiati

= http://dx.doi.org/10.20473/jr.v3-I.3.2017.67-73
Abstract views = 103 times | views = 301 times

Abstract


Background: The Multi Drug Resistance Tuberculosis (MDR-TB) prevalence rate is by 6900 in which there are 1.9% of new cases and 12 % of cases fail. Indonesia ranks eighth out of 27 countries in the world. This study is aimed to investigate the characteristics of the new MDR TB patient demographic data, treatment, and side effects. Method: This research was analyzed retrospective data of the Medical Record (MR). Data were analyzed qualitatively. Results: The number of new patients are 82 people consisting of 41 men and 41 women. About 35 patients came from Surabaya and 47 were from outside Surabaya. Among those, 28 patients are 51–60 years old. Patients in the intensive phase (0–8 month) were 47 patient and 35 patients were in the continue phase 9–24 month. The main cause is the highest MDR-TB relapse 33 patients. Cycloserin and ethionamide prescribed to all of the subject followed by levofloxacin which is prescribed to 68 patients. The other medication were kanamycin, capreomycon, moxifloxacin and Para Amino Salicylat (PAS) which administered to 27,14,7 patient consecutively. Nausea is the one of the Adverse Drug reaction (ADR) that is preverly emerged. There were 30 patients complary this ADR and treatment which Omeprazole and Ranitidin. Conclusion: Characteristics of patients greatly differed between patients categories. In Soetomo hospital effort should be made to improve management case, drug and prevent or eliminate adverse drug reaction.

Keywords


MDR TB, patient characteristic, side effects

Full Text:

PDF

References


WHO. Global Tuberculosis Report 20th Edition. Vol 20. Switzerland; 2015. doi:10.1017/CBO9781107415324.004

RI K. Pedoman Nasional Pengendalian Tuberkulosis. Jakarta: Kementrian Kesehatan Republik Indonesia.; 2014.

M-Y C. MDR-TB Patients with Cavitary Lesions and Resistance Pattern of Multidrug Resistan. Inter J Tuberc Lung Dis. 2015;19:525-530.

WHO. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report On Surveillance and Response. Switzerland.: WHO Press; 2010.

Jonshon, R., Streicher, E.M., Louw, G.E., Warren, R.M., Van Helden, P.D., Victor TC. Drug Resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol. 2006;8(2).

Zhang, Y., Yew W-W. Mechanisms of Drug Resistance in Mycobaterium tuberculosis: update 2015. Int J Tuberc Lung Dis. 2015;19(11):127.

Da Silva, P.E.A., Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011;66:1417–1430. doi:10.1093/jac/dkr173

WHO. Comparion Handbook to the WHO Guidline for the Programmatic Management of Drug-Resistant Tuberculosisi. Management of Drug-Resistant Tuberculosis. Geneva: WHO; 2014.

CDC C for DC& P. Prevention and Control of Tuberculosis in Correctional and Detention Facilities MMVR. 2006. 55.

Nawas. Prevention & Control of Tuberculosis in Correctional and Detection Weekly Report. Department of Health and Human Services Center For Disease Control & Prevention; 2010.

WHO. Companion Handbook to The WHO Guidelines for The Programmatic Management Of Drug-Resistant Tuberculosis. Switzerland: WHO Press; 2014.

Elmi OS, Hasan H, Abdullah S. Mat Jeab MZ Bin Alwi NN. J. Infect Dev Stries Multi Drug Resistant Tuberculosis and Risk Factors Associated With Its Development; A Retrospective Study. 2015.

Alena Skrahina, Henadz Hurevich, Aksana Zalutskaya, Eugeni Sanalchyk, Andrei Astrauko, Sven Hoffner, valiantsin Rosuvich, Andrei dadu, Bierpaolo de Colombani, Masoud Dara Wayne van Gerert MZ. Multi Drug Resistant Tuberculosis TB Belarus; The Size of The Problem and Associated Risk Factor. Republican scientific and Practical Centre For Pulmonology and Tuberculosisi, Avenue Dolginov Skitrakt 157, 220053 Mink Belarus; 2012.

Kell E Dooley, Quafae Lancou, Iragi Grali, Janine Knudsen, My Driss Elmes Saoudi IC and RE. Risk Factors for Tuberculosis Treatment Failure, Defaulth or Relapse and Out Comes of ReTreatment in Morocco. 2011.

Meyer K. Tuberculosis, Multi Drug Resistant. Dir Unit Tuberc Oper Policy Res Med Res Counc Pretoris. 2005;25(2).

WHO. 6. Management of MDR TB; A Field Guides A Companion Document to Guidelines for Programmatic Management of Drug –Resitant Tuberculosis Integrated Management of Adolescent and Adult Illness (IMAI). Geneva; 2009.

Hickjy AJ. Drug Delivery System For Tuberculosis Prevention and Treatment Advances in Pharmaceutical Technology. 2014.

Chambers HF, Turner J, Scheeter GF, Kawanura M H. Randomized Trial To Optimize Treatment of Multi Drug Resistant. 2005.

M.E, Huth AJR and AGC. Mehanism of Aminoglycoside Ototoxicity and Targets of Hair Cell Protection. (Otolaryngology S of MIJ of, ed.). Department of OtoLaryngology-Head and Neck Surgery, Stanford University; 2011.

Health CITC (CITC) and CD of P. Tuberculosis Drug Information Guide 2 Nd Edition.; 2011.

Kesehatan BP dan PKK. Riset Kesehatan Dasar. Jakarta: Departemen Kesehatan RI; 2013.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Jurnal Respirasi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

View My Satats

Indexed by: